ECSP19089214A - Inhibidores de quinasa y usos de los mismos - Google Patents

Inhibidores de quinasa y usos de los mismos

Info

Publication number
ECSP19089214A
ECSP19089214A ECSENADI201989214A ECDI201989214A ECSP19089214A EC SP19089214 A ECSP19089214 A EC SP19089214A EC SENADI201989214 A ECSENADI201989214 A EC SENADI201989214A EC DI201989214 A ECDI201989214 A EC DI201989214A EC SP19089214 A ECSP19089214 A EC SP19089214A
Authority
EC
Ecuador
Prior art keywords
kinase inhibitors
intermediates
compositions
compounds
processes
Prior art date
Application number
ECSENADI201989214A
Other languages
English (en)
Inventor
Vicente Fidalgo Javier De
Elena Serra
Colin Philip Leslie
Cinzia Maria Francini
Anthony A Estrada
Brian Fox
Cheng Hu
Christopher R H Hale
Arun Thottumkara
Zachary K Sweeney
Jianwen A Feng
Maksim Osipov
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of ECSP19089214A publication Critical patent/ECSP19089214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente descripción se refiere generalmente a compuestos y composiciones, intermedios, procedimientos para su preparación, y su uso como inhibidores de quinasa.
ECSENADI201989214A 2017-05-17 2019-12-16 Inhibidores de quinasa y usos de los mismos ECSP19089214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762507698P 2017-05-17 2017-05-17
US201862664895P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
ECSP19089214A true ECSP19089214A (es) 2020-05-29

Family

ID=64274744

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201989214A ECSP19089214A (es) 2017-05-17 2019-12-16 Inhibidores de quinasa y usos de los mismos

Country Status (21)

Country Link
US (3) US11203600B2 (es)
EP (1) EP3624797A4 (es)
JP (2) JP7064512B2 (es)
KR (1) KR102638151B1 (es)
CN (3) CN110913858B (es)
AU (1) AU2018269743B2 (es)
BR (1) BR112019023918A2 (es)
CA (1) CA3063934A1 (es)
CL (1) CL2019003263A1 (es)
CO (1) CO2019012957A2 (es)
CR (1) CR20190566A (es)
DO (1) DOP2019000290A (es)
EC (1) ECSP19089214A (es)
IL (1) IL270648B2 (es)
MX (2) MX2019013645A (es)
MY (1) MY200328A (es)
PE (2) PE20241932A1 (es)
PH (1) PH12019550235A1 (es)
SG (1) SG10201913927VA (es)
TW (1) TWI794232B (es)
WO (1) WO2018213632A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081923A1 (en) * 2018-10-19 2020-04-23 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
IL291665B2 (en) * 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
TW202535863A (zh) 2020-02-13 2025-09-16 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
KR200493347Y1 (ko) 2020-07-06 2021-03-17 박혜진 휴대가 용이한 마스크
AU2022222458A1 (en) * 2021-02-19 2023-08-24 Kalvista Pharmaceuticals Limited Factor xiia inhibitors
US20240228506A1 (en) * 2021-04-27 2024-07-11 Merck Sharp & Dohme Llc Ripk1 inhibitors and methods of use
EP4329765A4 (en) * 2021-04-27 2025-06-11 Merck Sharp & Dohme LLC Phenylazepines as RIPK1 inhibitors and methods of using them
KR20240099451A (ko) 2021-11-11 2024-06-28 젠자임 코포레이션 Ripk1 억제제로서의 이속사졸리딘 및 이의 용도
WO2024025817A1 (en) * 2022-07-25 2024-02-01 Denali Therapeutics Inc. Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5- dihydro-2h-pyrido[3,4-f][l,4]oxazepine-9-carbonitrile
TW202412812A (zh) * 2022-08-23 2024-04-01 美商建新公司 用於治療受體相互作用蛋白激酶１介導的疾病的方法
TW202444357A (zh) * 2023-01-23 2024-11-16 美商健臻公司 ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶并［３，４－ｆ］［１，４］氧氮呯－９－甲腈之藥品調配物
WO2025006575A1 (en) * 2023-06-27 2025-01-02 Genzyme Corporation Process for preparing 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido[3,4-f][l,4]oxazepine-9-carbonitrile
CN120365288A (zh) * 2024-01-23 2025-07-25 南京天印健华医药科技有限公司 作为ripk1抑制剂的杂环化合物
CN120365287A (zh) * 2024-01-23 2025-07-25 南京天印健华医药科技有限公司 作为ripk1抑制剂的杂环化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3861187B2 (ja) * 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
PL362048A1 (en) * 2000-09-27 2004-10-18 Ajinomoto Co, Inc. Benzodiazepine derivative
RU2456287C1 (ru) * 2011-05-20 2012-07-20 Николай Филиппович Савчук Стимуляторы секреции инкретиновых гормонов, способы их получения и применения
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
TWI638815B (zh) * 2013-02-15 2018-10-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（一）
CN104059068B (zh) * 2013-03-20 2017-02-08 中国科学院上海药物研究所 β‑氨基羰基类化合物、其制备方法、药物组合物及其用途
SG11201708622UA (en) * 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
UY36680A (es) * 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
DK3782996T3 (da) * 2015-06-15 2024-04-22 Glaxosmithkline Ip Dev Ltd NRF2-regulatorer

Also Published As

Publication number Publication date
MY200328A (en) 2023-12-20
US12129263B2 (en) 2024-10-29
EP3624797A1 (en) 2020-03-25
CN110913858A (zh) 2020-03-24
EP3624797A4 (en) 2021-07-21
IL270648B2 (en) 2024-03-01
MX2022010755A (es) 2022-09-23
DOP2019000290A (es) 2020-03-15
CR20190566A (es) 2020-06-14
BR112019023918A2 (pt) 2020-06-02
US20200087319A1 (en) 2020-03-19
CN110913858B (zh) 2024-09-24
PE20200729A1 (es) 2020-07-23
US20250011338A1 (en) 2025-01-09
KR20200006125A (ko) 2020-01-17
PE20241932A1 (es) 2024-09-24
PH12019550235A1 (en) 2020-07-20
CN119285572A (zh) 2025-01-10
CO2019012957A2 (es) 2020-05-29
WO2018213632A1 (en) 2018-11-22
IL270648B1 (en) 2023-11-01
IL270648A (es) 2020-01-30
AU2018269743B2 (en) 2024-01-11
SG10201913927VA (en) 2020-03-30
AU2018269743A1 (en) 2020-01-16
MX2019013645A (es) 2020-09-17
CL2019003263A1 (es) 2020-04-17
CA3063934A1 (en) 2018-11-22
US11203600B2 (en) 2021-12-21
US20220041620A1 (en) 2022-02-10
TW201900618A (zh) 2019-01-01
TWI794232B (zh) 2023-03-01
JP7064512B2 (ja) 2022-05-10
CN119264073A (zh) 2025-01-07
JP7241825B2 (ja) 2023-03-17
JP2021193116A (ja) 2021-12-23
KR102638151B1 (ko) 2024-02-16
JP2020520924A (ja) 2020-07-16

Similar Documents

Publication Publication Date Title
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
DOP2017000298A (es) Reguladores de nrf2
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
CR20150524A (es) Compuestos de heteroarilo y sus usos
CO2019006687A2 (es) Polimorfos
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
CO2019006673A2 (es) Polimorfos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
ECSP20021132A (es) Enantiómeros de tiazoles sustituidos compuestos antivirales
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
NI202000042A (es) Polimorfos
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
MX381489B (es) Compuesto biciclico y uso del mismo para la inhibicion de suv39h2.
UY38758A (es) Hidroxiisoxazolinas y derivados de las mismas